評論
打印
Doctors push back on the ‘right to try’ experimental treatments
醫生們紛紛推遲“嘗試實驗藥物的權利”相關治療
By Alexandra Sifferlin
作者：Alexandra Sifferlin
NO ONE WANTS TO ARGUE AGAINST GIVING potentially beneficial drugs to people who need them.
沒有人會反對向有需要的人群提供可能有益的藥物這一做法。
But not everyone in the medical community is convinced that a national “right to try” policy,
然而，醫學界并非所有人都相信，“嘗試實驗藥物的權利”這一國家政策，
which would allow people with fatal illnesses to have access to drugs not yet approved by federal authorities, will make life better for patients.
該政策讓身患絕癥的人有了使用尚未獲得聯邦當局批準的藥物的機會，真的能給患者的生活帶來改善。
Such laws have already passed in dozens of states,
數十個州都已經通過了這些法律，
and the Senate passed a version of the federal bill in August.
參議院8月份也通過了相關的聯邦法案。
Now, as the House of Representatives weighs a bill on the matter—
如今，因為下議院還在就此事權衡一個法案——
a proposal that President Donald Trump lauded in his Jan.30 State of the Union address—
特朗普1月30日發表國情咨文演講時曾經公開稱贊過該提案——
doctors and medical ethicists are sounding an alarm.
醫生和醫學倫理學家便紛紛敲響了警鐘。
For a drug to be approved for use in the U.S.,
美國的藥物要通過批準投入使用，
it must undergo several rounds of clinical testing.
得經過數輪的臨床試驗。
The U.S. Food and Drug Administration (FDA)—the agency that oversees that approval process—
但美國食品和藥物管理局（FDA） - 監督批準程序的機構 -
does have a system in place for getting unapproved drugs to people who need them,
的確有相關的機制給有需要的患者提供尚未批準的藥物，
often referred to as compassionate use or expanded access.
這一機制通常被稱之為“同情用藥”或“擴大使用”。
譯文由可可原創，僅供學習交流使用，未經許可請勿轉載。
